Clinical Trial Detail

NCT ID NCT03250338
Title Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Arog Pharmaceuticals, Inc.
Indications

acute myeloid leukemia

Therapies

Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone

Crenolanib + Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone

Age Groups: senior adult

Additional content available in CKB BOOST